In this study, we aimed to evaluate intrinsic and acquired resistance to anti-EGFR therapy in prospectively collected tumour samples of KRAS wt metastatic CRC (mCRC) patients who were administered cetuximab-containing regimens in real-world clinical care. This evidence concerns the gene EGFR and neoplasm.